Axitinib Plus Toripalimab as Second-line Treatment in Hepatobiliary Malignant Tumors
Status:
Recruiting
Trial end date:
2022-06-30
Target enrollment:
Participant gender:
Summary
The investigators design a phase II clinical study to explore the efficacy and safety of
axitinib plus toripalimab as a second-line treatment in patients with hepatobiliary malignant
tumors and to analyze potential biomarkers of therapeutic response.